Clinical Study
Transarterial Embolization for Hepatocellular Carcinoma: A Comparison between Nonspherical PVA and Microspheres
Table 2
Baseline demographics and tumoral characteristics.
| | Characteristics | PVA () | ME () | value |
| | Age (years) | 61 ± 8.3 | 60.4 ± 9.6 | 0.75 | | Gender (male) | 58.3% | 81.3% | 0.06 | | Caucasians (%) | 93% | 99% | 0.28 | | Body mass index (kg/m2) | 26.1 ± 4.2 | 26.4 ± 4.4 | 0.76 | | HCV positive (%) | 82.2% | 74.2% | 0.58 | | HCVRNA PCR qualit. (%) | 90.0% | 81.8% | 0.60 | | Alcohol induced cirrhosis (%) | 34.8% | 34.5% | 1.0 | | BCLC (%) | | | | | A | 36.0 | 25.0 | 0.36 | | B | 60.0 | 75.0 | | C | 3.3 | 0 | | Child-Pugh (%) | | | | | A | 43.8 | 59.4 | 0.25 | | B | 50.0 | 31.3 | | C | 6.3 | 9.4 | | MELD | 12.4 | 14.3 | 0.12 | | Performance status (0) | 93.8% | 84.4% | 0.26 | | Aspartate transaminase (U/L) | 36.6 | 37.6 | 0.85 | | Alanine transaminase (U/L) | 62.3 | 79.7 | 0.85 | | Gamma-glutamyl transferase (U/L) | 134.9 | 117.2 | 0.48 | | Platelets (×1000/UL) | 100.7 | 115.6 | 0.25 | | Prothrombin time (%) | 72.9 | 76.9 | 0.26 | | Albumin (U/L) | 3.25 | 3.46 | 0.22 | | Total bilirubin (mg/dL) | 1.49 | 1.2 | 0.08 | | Alpha-fetoprotein (ng/mL) | (44) 2747 | (28) 1027 | 0.22 | | Creatinine | 0.93 | 0.95 | 0.72 | | CTMD | 65.0% | 51.0% | 0.34 | | Tumor size (cm) | 4.7 | 5.4 | 0.11 | | Number of tumors | | | | | 1 | 66.7% | 25.0% | 0.49 | | 3 | 29.2% | 62.5% | 0.48 | | 3 | 4.2% | 12.5% | 0.48 | | Number of transarterial embolizations | 2.3 | 2.1 | 0.19 |
|
|
PVA: polyvinyl alcohol; ME: microspheres; HCV, hepatitis C virus; HCVRNA PCR qualit.: C-reactive protein qualitative RNA hepatitis C virus; BCLC: Barcelona Clinic Liver Cancer; MELD: Model for End-Stage Liver Disease; CTMD: computed tomography multidetector.
|
